Nanotherapeutics: From Laboratory to Clinic, 1st Edition (e-Book) book cover


From Laboratory to Clinic, 1st Edition

By Ezharul Hoque Chowdhury

CRC Press

354 pages

Purchasing Options:$ = USD
Hardback: 9781498707510
pub: 2016-04-27
eBook (VitalSource) : 9780429183317
pub: 2016-04-21
from $28.98

FREE Standard Shipping!


The emergence of nanotherapeutics is attributable to the integration of nanotechnology, recombinant DNA technology, and synthetic organic chemistry with medicine for treating critical human diseases in a more efficient and specific molecular approach than therapy with conventionally-designed and formulated drugs. Nanotherapeutics: From Laboratory t

Table of Contents

Emergence of nanotherapeutics: Challenges in classical drug transport versus macromolecular drug design. The ultimate destinations for delivery and release of nanotherapeutics. Diversity of bioactive nanoparticles from biological, chemical, and physical perspectives. Fabrication strategies for biofunctional nanoparticles. Interactions and orientation of therapeutic drugs in the vicinity of nanoparticles. Variable interactions of nanoparticles with blood, lymph, and extracellular and intracellular components. Pharmacokinetics and biodistribution of nanoparticles. Specific roles of nanoparticles in various steps of drug transport. Nanotechnology approaches to modulate transport, release, and bioavailability of classical and emerging therapeutics. Nanotechnology in the development of innovative treatment strategies. Nanoparticles for therapeutic delivery in animal models of different cancers. Nanoparticles for therapeutic delivery in animal models of other critical human diseases. Nanomedicine in clinical trials. Approved and commercialized nanomedicine. Current safety issues: Biodegradability, reactivity, and clearance. References.

About the Author

Dr. Ezharul Hoque Chowdhury is an associate professor and cluster leader of biomedical engineering under the Advanced Engineering Platform at Monash University (Sunway Campus). He obtained his Doctor of Engineering degree in 2003 at Tokyo Tech. Dr. Chowdhury has pioneered the development of pH-sensitive inorganic nanoparticles as smart tools for efficient and targeted intracellular delivery of genetic materials, gene-silencing elements, proteins, and classical anticancer drugs. He is currently applying this smart nanotechnology for the treatment of cancer, particularly breast carcinoma, and cardiovascular diseases, such as diabetes. Dr. Chowdhury holds six Japanese and US patents.

Subject Categories

BISAC Subject Codes/Headings:
MEDICAL / Pharmacology
MEDICAL / Pharmacy
SCIENCE / Biotechnology